Featured

As the year comes to a close, it’s a good time to pause and look back on everything we’ve achieved together in 2025. It’s been

MAC Clinical Research is proud to support Initiator Pharma as the full-service CRO partner for their upcoming Phase 2a clinical trial, as they take an

We are proud to announce the successful completion of Kariya Pharmaceuticals’ Phase I clinical trial for KP405, a brain-penetrant GLP-1/GIP analogue designed to slow the

The UK’s clinical research environment is changing, and quickly. Recent updates from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA)

Contract Research Organisations (CROs) are often associated with the operational side of clinical trials: patient recruitment, data management, site monitoring and logistics. While those tasks

We are pleased to share that the first patient has now been dosed in a Phase 2 clinical trial – a study exploring a new,

If you’re a researcher with a promising therapeutic, device or intervention, there comes a point where someone suggests taking it into a clinical trial. It

MAC Clinical Research is pleased to announce the successful dosing of the first participant in a Phase 2 clinical study investigating a psychedelic investigational compound

MAC Clinical Research and Kariya Pharmaceuticals are pleased to share the successful dosing of the first cohort in the Phase 1 Multiple Ascending Dose (MAD)

MAC Clinical Research (MAC) announces regulatory approval to initiate a PII clinical trial for mavatrep, an investigational, oral, TRPV1-receptor (transient receptor potential cation channel vanilloid